Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Role of Glucose Transporter 1 in Graft-Versus-Host Disease and Graft-Versus-Tumor Effect

Ying Huang, MD PhD, Yiqun Jiao, MD, Peijie Shi, MD PhD, Xiaoli Nie, MD PhD, Wei Huang, MD PhD, Michael Choi, Andrew N Macintyre, Amanda Nichols, Nancie J. MacIver, MD PhD, Nelson J. Chao, MDM.B.A, Jeffrey Rathmell, PhD, Benny J. Chen, MD

Blood (2017) 130 (Supplement 1): 1891.

https://doi.org/10.1182/blood.V130.Suppl_1.1891.1891

Published: 2017

Journal Articles

Adoptive Transfer Of Ex Vivo “Educated” CD4+CD25+FoxP3+ Regulatory T Cells Effectively Treats Acute Graft Versus Host Disease Preserving Graft Versus Tumor Effect

Antonio Pierini, MD, Dominik Schneidawind, MD, Mareike Florek, MD, Maite Alvarez, PhD, Yuqiong Pan, MD, Jeanette Baker, PhD, Everett Meyer, MD, PhD, Robert Negrin, MD

Blood (2013) 122 (21): 4485.

https://doi.org/10.1182/blood.V122.21.4485.4485

Published: 2013

Journal Articles

Perforin Is Important For Both CD4+ and CD8+ T Cell-Mediated Graft-Versus-Tumor Effect But Plays Differential Roles In CD4+ and CD8+ T Cell Expansion After Allogeneic Transplantation

Nicholas Leigh, Guanglin Bian, PhD, Wei Du, George L. Chen, MD, Hong Liu, MD, PhD, Philip L. McCarthy, Jr., MD, Xuefang Cao, PhD

Blood (2013) 122 (21): 3255.

https://doi.org/10.1182/blood.V122.21.3255.3255

Published: 2013

Journal Articles

Lymphodepletion Followed By Suicide-Gene-Transduced Donor Lymphocyte Infusion: A Strategy To Safely Enhance The Graft-Versus-Tumor Effect

Blood (2013) 122 (21): 153.

https://doi.org/10.1182/blood.V122.21.153.153

Published: 2013

Journal Articles

Cross-Presentation by Host CD8α + dendritic Cells Augments Graft-Versus-Tumor Effect without Aggravating Graft-Versus-Host Disease After Allogeneic BMT

Tomomi Toubai, MD, PhD, Yaping Sun, MD, PhD, Isao Tawara, MD, PhD, Chen Liu, PhD, Pavan Reddy, M.D.

Blood (2011) 118 (21): 310.

https://doi.org/10.1182/blood.V118.21.310.310

Published: 2011

Journal Articles

Graft-Versus-Tumor Effect In Patients with Graft-Versus-Host Disease Defined by NIH Consensus Criteria

Sung-Eun Lee, Byung-Sik Cho, Seung-Ah Yahng, Ki-Seong Eom, Yoo-Jin Kim, Hee-Je Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Dong-Wook Kim, Jong-Wook Lee, Woo-Sung Min, Chong-Won Park

Blood (2010) 116 (21): 2343.

https://doi.org/10.1182/blood.V116.21.2343.2343

Published: 2010

Journal Articles

Impact of I n Vivo T-Cell Depletion on Outcome of Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplantation (HCT) for Hematologic Malignanciesimpact of I n Vivo T-Cell Depletion on Outcome of Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies

Robert J Soiffer, MD, Jennifer LeRademacher, PhD, Vincent T Ho, MD, Fangyu Kan, MD, MS, Andrew Artz, MD, MS, Richard Champlin, Steven Devine, MD, Hillard M. Lazarus, MD, FACP, David I Marks, MB, BS, PHD, David Porter, MD, Edmund K. Waller, MD, PhD, Mary M. Horowitz, MD, MS, Mary Eapen, MBBS

Blood (2010) 116 (21): 2305.

https://doi.org/10.1182/blood.V116.21.2305.2305

Published: 2010

Journal Articles

Phase I Study of Transfer of CD8 Depleted Donor Leukocytes after Allogeneic Stem Cell Transplantation.

Guillermo Orti, MD, Karl Peggs, MD, Kirsty Thomson, MD, Emma Morris, MD, Mark Lowdell, PhD, Stephen Mackinnon, MD, Ronjon Chakraverty, MD

Blood (2008) 112 (11): 2203.

https://doi.org/10.1182/blood.V112.11.2203.2203

Published: 2008

Journal Articles

Adoptively-Infused NK Cells Maintain Their Antitumor Effects in Vivo in the Presence of CyclosporineA (CSA)

Hisayuki Yokoyama, Andreas Lundqvist, Maria Berg, Muthalagu Ramanathan, Rebecca Lopez, Aleah Smith, Nicole Gormley, Su Su, J. Phillip McCoy, Richard W. Childs, MD

Blood (2008) 112 (11): 2563.

https://doi.org/10.1182/blood.V112.11.2563.2563

Published: 2008

Journal Articles

Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NMHCT) for Patients Relapsing after Autologous Stem Cell Transplantation (autoHCT) for B Cell Non-Hodgkin Lymphoma (NHL)

Cesar O Freytes, MD, Jeanette Carreras, MPH, Mei-Jie Zhang, PhD, Ginna G. Laport, MD, Koen Van Besien, MD, Hillard M. Lazarus, MD, Parameswaran Hari, MD, MS

Blood (2008) 112 (11): 459.

https://doi.org/10.1182/blood.V112.11.459.459

Published: 2008

Journal Articles

The In Vivo Impact of Human Regulatory T Cells on the Graft Versus Tumor Effect.

Tuna Mutis, MD, PhD, Henk Rozemuller, PhD, Maarten E. Emmelot, Tineke Aarts-Riemens, Vivienne Verweij, Saskia Ebeling, PhD, Leo F. Verdonck, MD, PhD, Henk Lockhorst, MD, PhD, Anton Martens, PhD

Blood (2007) 110 (11): 349.

https://doi.org/10.1182/blood.V110.11.349.349

Published: 2007

Journal Articles

Are 2 cords better than 1?

Elizabeth Shpall, Marcos de Lima, Roy Jones, Richard Champlin

Blood (2007) 110 (8): 2789–2790.

https://doi.org/10.1182/blood-2007-07-097691

Published: 2007

Journal Articles

Partially HLA Matched, Non-Myeloablative Allogeneic Transplantation.

David A. Rizzieri, MD, Liang Piu Koh, MD, Gwynn D. Long, MD, Cristina Gasparetto, MD, Keith M. Sullivan, MD, Mitchell Horwitz, MD, John Chute, MD, Jerald Z. Gong, MD, Anand S. Lagoo, MD, Donna Niedzwiecki, PhD, Cong Xiao Lu, MD, Dawn Marshall, BS, Jeanette M. Dowell, MS, Nelson J. Chao, MD

Blood (2005) 106 (11): 2896.

https://doi.org/10.1182/blood.V106.11.2896.2896

Published: 2005

Journal Articles

Outcomes of Patients with Engraftment Syndrome (ES) Following Nonmyeloablative Hematopoietic Stem Cell Transplant (SCT) for Hematologic Malignancy(HM).

Erica Linden, MD, Steven L. McAfee, MD, Bimalangshu R. Dey, MD, Karen Ballen, MD, Susan Saidman, PhD, Christine Colby, PharmD, Megan Sykes, MD, Thomas R. Spitzer, MD

Blood (2005) 106 (11): 3661.

https://doi.org/10.1182/blood.V106.11.3661.3661

Published: 2005

Journal Articles

Identifying Patients at Risk of Early Relapse after Submyeloablative Allogeneic HSCT.

Jayesh Mehta, L. Gordon, M. Tallman, J. Winter, S. Williams, A. Evens, O. Frankfurt, D. Grinblatt, L. Kaminer, R. Meagher, S. Singhal

Blood (2005) 106 (11): 5390.

https://doi.org/10.1182/blood.V106.11.5390.5390

Published: 2005

Journal Articles

Protection Against Graft-Versus-Host Disease and Retention of Graft-Versus-Tumor Effect after Allogeneic BMT in Mice Conditioned with TLI and Anti-Thymocyte Serum.

Asha Pillai, MD, Pearline Teo, BS, Samuel Strober, MD

Blood (2004) 104 (11): 3049.

https://doi.org/10.1182/blood.V104.11.3049.3049

Published: 2004

Journal Articles

Donor CD8+ T Cells Facilitate Graft-Versus-Tumor Effect Via Alloantigen Rather Than Tumor-Specific Antigen Recognition Following Murine Myeloablative BMT.

Asha B. Pillai, MD, Pearline A. Teo, BS, Aditi Mukhopadhyay, BS, Samuel Strober, MD

Blood (2004) 104 (11): 3051.

https://doi.org/10.1182/blood.V104.11.3051.3051

Published: 2004

Journal Articles

Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)–producing tumor vaccines

Ivan Borrello, Eduardo M. Sotomayor, Frédérique-Marie Rattis, Sara K. Cooke, Lingping Gu, Hyam I. Levitsky

Blood (2000) 95 (10): 3011–3019.

https://doi.org/10.1182/blood.V95.10.3011

Published: 2000

NARROW

Role of Glucose Transporter 1 in Graft-Versus-Host Disease and Graft-Versus-Tumor Effect

Adoptive Transfer Of Ex Vivo “Educated” CD4+CD25+FoxP3+ Regulatory T Cells Effectively Treats Acute Graft Versus Host Disease Preserving Graft Versus Tumor Effect

Perforin Is Important For Both CD4+ and CD8+ T Cell-Mediated Graft-Versus-Tumor Effect But Plays Differential Roles In CD4+ and CD8+ T Cell Expansion After Allogeneic Transplantation

Lymphodepletion Followed By Suicide-Gene-Transduced Donor Lymphocyte Infusion: A Strategy To Safely Enhance The Graft-Versus-Tumor Effect

Cross-Presentation by Host CD8α + dendritic Cells Augments Graft-Versus-Tumor Effect without Aggravating Graft-Versus-Host Disease After Allogeneic BMT

Graft-Versus-Tumor Effect In Patients with Graft-Versus-Host Disease Defined by NIH Consensus Criteria

Phase I Study of Transfer of CD8 Depleted Donor Leukocytes after Allogeneic Stem Cell Transplantation.

Adoptively-Infused NK Cells Maintain Their Antitumor Effects in Vivo in the Presence of CyclosporineA (CSA)

Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NMHCT) for Patients Relapsing after Autologous Stem Cell Transplantation (autoHCT) for B Cell Non-Hodgkin Lymphoma (NHL)

The In Vivo Impact of Human Regulatory T Cells on the Graft Versus Tumor Effect.

Are 2 cords better than 1?

Partially HLA Matched, Non-Myeloablative Allogeneic Transplantation.

Outcomes of Patients with Engraftment Syndrome (ES) Following Nonmyeloablative Hematopoietic Stem Cell Transplant (SCT) for Hematologic Malignancy(HM).

Identifying Patients at Risk of Early Relapse after Submyeloablative Allogeneic HSCT.

Protection Against Graft-Versus-Host Disease and Retention of Graft-Versus-Tumor Effect after Allogeneic BMT in Mice Conditioned with TLI and Anti-Thymocyte Serum.

Donor CD8+ T Cells Facilitate Graft-Versus-Tumor Effect Via Alloantigen Rather Than Tumor-Specific Antigen Recognition Following Murine Myeloablative BMT.

Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)–producing tumor vaccines

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only